We have previously demonstrated altered p16 and RB protein status in non-small-cell lung cancers (NSCLCs) and their potential synergistic effect with altered p53 protein on proliferative activity (Kinoshita et al (1996) Cancer Res56: 5557–5562). This evidence concerns the gene CDKN2A and non-small cell lung carcinoma.